Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma

  • Authors:
    • Feifei Wu
    • Jing Wang
    • Xiaoyan Ke
  • View Affiliations

  • Published online on: February 17, 2016
  • Pages: 1561-1570
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


B7 homologue 6 (B7-H6) is a new member of the B7 family molecules and is selectively expressed on tumor cells, especially in hematologic malignancies. However, the role of B7-H6 in lymphoma progression and chemosensitivity remains unclear. We determined the effects of downregulating B7-H6 expression on tumorigenesis and chemosensitivity in B-cell lymphoma. Stable B7-H6 knockdown in CA46 cells was established with a lentiviral system. The expression of mRNA was measured by PCR while protein expression was detected by western blotting and flow cytometry. Cell viability, apoptosis and cell cycle distribution were analyzed using CCK-8, colony formation and flow cytometry assays, respectively. Cell migration and invasion were determined using the Transwell chamber assay. B7-H6 was widely expressed in B-cell lymphomas. Knockdown of B7-H6 inhibited cell proliferation, colony formation and migration and invasion of lymphoma cells. After B7-H6 silencing, CA46 cells were arrested in G0/G1 phase. Moreover, the silencing of B7-H6 increased cell apoptosis and sensitivity to vincristine and dexamethasone. Investigation of expression of downstream targets of STAT3 supported a theory in which B7-H6 knockdown may confer an antitumor effect via abrogation of the STAT3 pathway. This study demonstrates that B7-H6 plays an important role in the pathogenesis and chemosensitivity of lymphoma. B7-H6 is therefore a potential clinical biomarker and therapeutic target in B-cell lymphomas.


Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy arising from lymphoid tissue worldwide (1), ~85% of which derive from B lymphocytes. The overall survival of B-cell lymphomas has significantly improved since the FDA approval and clinical use of rituximab, a monoclonal antibody targeting CD20-positive malignant B cells (2). However, relapse and resistance are obstacles to the cure of B-NHL patients, underscoring the need for more effective therapies. Immunotherapy is one promising new direction for lymphoma as it is for many other malignancies (2).

The B7 family is a group of molecules important for the regulation of tumor immunity, and can profoundly affect tumor progression and elimination (38). Monoclonal antibodies targeting B7 molecules including CD80 (9), PD-L1 (10), PD-L2 (11) and B7-H3 (12), have shown promising results in lymphomas, melanoma, non-small cell lung cancer and other cancers. B7-H6, also called NCR3L1 or DKFZp686O24166, is a new member of the B7 family identified by Brandt et al in 2009 (3). B7-H6 is a 454-aa-long type I transmembrane protein that shows considerable homology with PD-L1 and B7-H3 (3), both of which contribute to the oncogenesis and chemoresistance of lymphomas (13,14). The receptor of B7-H6, NKp30, is an activating NK-cell receptor. The interaction of tumor membrane-bound B7-H6 and NKp30 leads to the activation of NK cells and to the lysis of tumor cells (3,15). A fusion protein of B7-H6 ectodomain and CD20 single-chain fragment stimulates NKp30-mediated NK cell cytotoxicity (7). Moreover, the NKp30-based chimeric antigen receptor promotes T-cell effector functions and antitumor efficacy through recognizing and killing B7-H6-positive tumor cells (16). These results indicate that B7-H6 may be a potential therapeutic target in cancer therapy.

It is reported that B7-H6 is widely and specifically expressed on tumor cells including melanomas (3,17), cervical carcinomas (3), ovarian carcinomas (3,4), liver cancer (18), gastric cancer (19), lung cancer (20), neuroblastoma (6), T and B lymphomas and myeloid leukemia (3,8), but is absent from normal tissues (3). B7-H6 is associated with tumor progression and metastasis in ovarian cancers (4). To date, however, little is known about the oncogenic role of B7-H6 in lymphomas. Hence, we established a B7-H6 knockdown cell line for the first time to investigate the impact of B7-H6 on cell proliferation, apoptosis, cell cycle, migration, invasion and chemosensitivity. The underlying mechanisms were also investigated, with the aim of providing a basis for clinical therapy.

Materials and methods

Cell lines and cell culture

Raji, CA46, Z138, Maver and HeLa cell lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Raji, CA46 and Z138 cells were cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 2 mM L-glutamine, 10% FBS (Hyclone, South Logan, UT, USA), 100 U/ml penicillin and 100 μg/ml streptomycin. Maver and HeLa cells were respectively cultured in IMDM and DMEM medium. Cells were routinely cultured at 37°C in a humidified incubator containing 5% CO2 (14). The primary tumor proteins were obtained from Peking University Third Hospital. The study was approved by the local ethics committee and all patients provided written informed consent.

Lentivirus-based RNA interference transfection and generation of stable cell lines

The human B7-H6 targeting small hairpin RNA (shRNA) was designed and synthesized by Life Technologies (Lifetech, Beijing, China). The sequence was 5′-CGGCACAGTCTTTCTGAAACT-3′. A negative non-target control shRNA was also used with the sequence 5′-CAAC AAGATGAAGAGCACCAA-3′. These shRNAs were used to generate recombinant lentiviral particles as described (14). CA46 cells were infected in the presence of 8 μg/ml of polybrene (Sigma, Milwaukee, WI, USA) and selected by flow cytometry 72 h later. The B7-H6 knockdown was confirmed by RT-PCR, western blotting and flow cytometry. The infected cells comprised B7-H6shRNA (CA46shB7-H6) and non-targeted control (CA46shCtrl) groups, while non-infected cells (CA46) constituted an additional control group. These three cell lines were used for the following experiments.

RT-PCR and quantitative PCR

Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed to cDNA using Reverse Transcription System (Promega, Madison, WI, USA) according to the manufacturer's instructions. cDNA (100 ng) was subjected to PCR amplification in a total volume of 25 μl according to the manufacturer's protocols. The primer sequences of the PCR were as follows: B7-H6 forward, 5′-ACAGTAAATGCCTGATGGACCT-3′; B7-H6 reverse, 5′-ATTGGGTATGTGAATGCTGGT-3′; β-actin forward, 5′-TGACGTGGACATCCGCAAAG-3′; β-actin reverse, 5′-CTGGAAGGTGGACAGCGAGG-3′. The PCR products were run on agarose gels and visualized under ultraviolet. Quantitative PCR was conducted with SuperReal PreMix Plus kit (Tiangen, Beijing, China) in a volume of 20 μl according to the manufacturer's instructions. The primer sequences of quantitative PCR were as follows: B7-H6 forward, 5′-GCACTTCCTCACCGCTAATG-3′; B7-H6 reverse, 5′-AGCCTGTTTCCTTTCGCTATT-3′. The ratio of expression of B7-H6 to β-actin mRNA was calculated.

Western blotting

Cytoplasmic proteins were extracted from primary and culture cells by lysis buffer composed of 50 mmol/l Tris-HCl (pH 7.5), 150 mmol/l NaCl, 5 mmol/l EDTA, 0.5% Nonidet P-40, 5 mmol/l dithiothreitol and 10 mmol/l NaF, and containing protease inhibitor cocktail (Applygen, Beijing, China). Proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. After blocking, the membranes were sequentially incubated with primary antibodies, including anti-B7-H6, anti-c-Myc, anti-Rb, and anti-phospho-Rb (Abcam, Cambridge, MA, USA); anti-Survivin, anti-CDK4, anti-CDK6, anti-p21, anti-Bad, anti-MMP-2, anti-MMP-9, and anti-β-actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA); and anti-Cyclin D1, anti-Bcl-2, anti-Bcl-xL, anti-Bax, anti-Caspase-3, anti-Caspase-8, anti-STAT3, anti-phospho-STAT3 (Ser727 and Tyr705), anti-ERK1/2 and phospho-ERK1/2 (CST, Beverly, MA, USA), and then with anti-rabbit or mouse secondary antibodies (LI-COR, Lincoln, NE, USA). Fluorescent bands were visualized using an Odyssey infrared imaging system (LI-COR).

Flow cytometry

Single cell suspensions were stained with B7-H6-APC or IgG1-APC (R&D, Minneapolis, MN, USA) antibodies on ice for 30 min, cells were analyzed using a flow cytometry system (FACSCalibur; BD Biosciences, San Jose, CA, USA).

Colony formation assay

An 800 single-cell suspension was resuspended in 1 ml medium with 20% FBS and 0.9% methyl-cellulose medium (Sigma, St. Louis, MO, USA). Samples were plated in 24-well plates and incubated for 14 days. A colony with >50 cells was counted as a positive colony. The colony-forming ability was calculated to be the number of colonies in the test group expressed as a percentage of the number of colonies in the control group (13).

CCK-8 assay

The Cell Counting Kit-8 (CCK-8; Dojindo, Tokyo, Japan) was used to study cell viability according to the manufacturer's instructions. A cell suspension was inoculated into a 96-well plate (2×104 cells/well) and incubated for 0, 24, 48 or 72 h. At every time-point, 10 μl CCK-8 was added to each well and the plate was incubated for 3 h at 37°C and 5% CO2. Absorbance was measured at 450 nm using a microplate reader.

For cell viability assay, cells were seeded in 96-well plates and exposed to various concentrations of VCR (0, 1.5, 3, 6, 12.5, 25, 50, 75 and 100 μg/ml) or Dex (0, 1.5, 3, 6, 12.5, 25, 50, 100, 200, 400, 800, 1,200, 1,600 and 2,400 μg/ml) for 24 h. A CCK-8 assay was used to detect the chemotherapeutic sensitivity of cells. The assay was performed with six replicates (n=6) for each group and repeated at least three times.

Cell apoptosis analysis

To explore the effect of B7-H6 knockdown on cell apoptosis, cells were serum starved for 24 h. To explore the B7-H6 knockdown on the sensitivity to VCR and Dex, cells were seeded into 6-well plates at a cell density of 1×106 cells/well and treated with or without VCR (25 μg/ml) or Dex (200 μg/ml) for 24 h. Cells were then harvested and apoptosis was analyzed by FACSCalibur cytometer using Annexin V-APC and 7-AAD (BD Pharmingen, San Jose, CA, USA) according to the manufacturer's instructions. CellQuest software was used for data analysis.

Cell cycle analysis

To explore the effect of B7-H6 knockdown on the cell cycle, cells were serum starved for 24 h. Cells were then collected, washed and fixed in 70% ethanol overnight at 4°C. Cellular DNA was stained with propidium iodide (PI) (Beyotime, Nangtong, China) in the dark for 10 min at room temperature. DNA content and cell number were determined using a FACSCalibur cytometer. The data were analyzed using the ModFit program (Verify Software House, Cambridge, UK).

Cell migration and invasion assay

Migration and invasion assays were performed using 24-well Transwell cell culture chambers (Corning, NY, USA) or Matrigel-coated invasion chambers. Cells (5×105 cells/well) were serum starved for 24 h and placed in the upper chamber in serum-free medium. Medium containing 10% FBS was placed in the lower chamber as a chemoattractant. After 24 h of incubation, the migrated cells in the lower chamber were collected and resuspended. Non-invading cells were removed with a cotton-tipped swab from the top of Matrigel and invading cells were fixed and stained with 0.1% crystal violet. Cells were photographed and counted in six random microscopic fields.

Statistical analysis

Statistical analysis was performed using SPSS 18.0 software (Chicago, IL, USA). Data are shown as mean± SD of triplicate for each experiment. Differences between groups were evaluated using SPSS 18.0 software. Data are shown as mean ± SD of all replicates for each experiment. Differences between groups were evaluated using ANOVA. P<0.05 was considered to be statistically significant.


B7-H6 is expressed in B-cell non-Hodgkin lymphomas

Studies have shown that B7-H6 mRNA is absent in normal tissues and relatively abundant in tumor cells (3). To investigate the role of B7-H6 in B-cell NHL, we first detected B7-H6 expression at the mRNA level in patients with B-cell NHL and healthy donors. Using the HeLa cell line as a positive control, we found that B7-H6 was widely and heterogeneously expressed in B-cell NHLs including chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL) and B-cell acute lymphocytic lymphoma (B-ALL) (Fig. 1A), but was absent in healthy donors' peripheral mononuclear cells (PMNC) at the mRNA level (data not shown). We also measured the expression of B7-H6 at nuclear/cytosolic level in 8 B-cell NHL patients including CLL (n=3), DLBCL (n=3), MCL (n=1) and B-ALL (n=1). B7-H6 expression was observed in tumor cells from 4 patients (2 patients with CLL, 1 patient with MCL and 1 patient with DLBCL; Fig. 1B). However, we did not detect B7-H6 in PMNC of 4 healthy donors (data not shown). Furthermore, human B-cell lymphoma cell lines (Raji, CA46, Z138 and Maver) expressed B7-H6 at the level of mRNA (Fig. 1C), nuclear/cytosolic protein (Fig. 1D) and membrane protein (Fig. 1E). These results indicated that B7-H6 is widely expressed in B-cell lymphoma specimen and cell lines.

The establishment of a B7-H6 stable knockdown cell line

To investigate the role of B7-H6 in B-cell lymphoma, CA46 cells were selected for in vitro studies as they expressed a high and steady level of endogenous B7-H6 (Fig. 1C–E). B7-H6 knockdown in CA46 cells was performed using lentivirus transduction to stably express shRNA targeting B7-H6. There was no significant difference of B7-H6 expression between the CA46 and CA46shCtrl (non-target control shRNA) groups at the mRNA and protein level (P>0.05). However, B7-H6 expression in the CA46shB7-H6 group containing the B7-H6-targetting shRNA, was significantly decreased compared to the CA46 group (P<0.01). The inhibition rates of mRNA expression in CA46 cells was 74.4% (Fig. 2A and C), whereas the nuclear/cytosolic protein was reduced by 77.9% (Fig. 2B) and the membrane protein was inhibited by 60.1% (Fig. 2D).

B7-H6 knockdown inhibits tumor cell proliferation

To evaluate the effects of B7-H6 knockdown on tumor cell proliferation, colony forming and CCK-8 assays were performed. The colony forming ability of the CA46shB7-H6 group was decreased by 73.8% compared to the CA46 group (P<0.01; Fig. 3A and B). The cell proliferation of the CA46shB7-H6 group was decreased by 33.8, 38.9 and 25.8% after 24, 48 and 72 h respectively, compared to the CA46 group (P<0.05; Fig. 3C). Furthermore, we assessed markers reflecting tumor cell proliferation ability. The expressions of PCNA, c-Myc and Survivin in CA46 cells were significantly decreased by 74.1, 21.6 and 55.2% compared to the CA46shB7-H6 group (P<0.05; Fig. 3D).

B7-H6 knockdown induces apoptosis and inhibits cell cycle progression

To explore the effects of B7-H6 knockdown on cell apoptosis and cell cycle, we analyzed apoptotic rates and cell cycle distribution by flow cytometry. Our results showed that there were 15.09% apoptotic cells in CA46shB7-H6 cells compared to only 6.32% in CA46 cells (P<0.001; Fig. 4A and B). We also detected the proteins involved in apoptosis by western blotting. Expression of anti-apoptotic proteins including Bcl-2, Bcl-xL, Caspase-3 and -8 was decreased, and pro-apoptotic proteins including bax and bad were increased in CA46shB7-H6 cells compared to CA46 and CA46shCtrl cells (P<0.05; Fig. 4C). The percentage of cells in G0/G1 phase was 43.72% in CA46 shB7-H6 cells and 28.56% in CA46 cells (P<0.001; Fig. 5A and B). To further understand the effect of B7-H6 on the cell cycle progression, we measured expression of cell cycle regulatory proteins. Cyclin D1, CDK4, CDK6 and phospho-Rb expression was significantly decreased, while Rb and p21 expression was increased in CA46shB7-H6 cells in comparison to CA46 or CA46shCtrl cells (P<0.05; Fig. 5C). The data indicate that knockdown of B7-H6 in CA46 cells increases apoptosis and induces G0/G1 cycle arrest.

B7-H6 knockdown inhibits tumor cell migration and invasion

We performed Transwell migration and invasion assays to determine whether B7-H6 acts as a regulator of cell migration and invasion. The cell migration assay showed that the migration ability was reduced by 67.3% in CA46shB7-H6 cells compared to CA46 cells (P<0.01). Furthermore, the invasion assay showed that knockdown of B7-H6 reduced cell invasion ability by 59.4% (P<0.01; Fig. 6A and B). We also measured the expression of crucial proteins involved in cell migration and invasion, and found that expression of MMP-2 and MMP-9 was lower in CA46shB7-H6 cells than in CA46 cells (Fig. 6C). These results indicate that knockdown of B7-H6 could impair cell migration and invasion ability via downregulating the expression of MMP-2 and MMP-9.

B7-H6 knockdown enhances the sensitivity of tumor cells to chemotherapy

To explore whether knockdown of B7-H6 would sensitize lymphoma cells to chemotherapeutic drugs, we chose the frontline drugs in the clinical regimen for NHL, namely VCR and Dex. Cell viability was measured after cells were treated with different concentrations of VCR and Dex for 24 h. The cell survival rates in the CA46shB7-H6 group were significantly decreased compared with CA46 or CA46shCtrl group (P<0.01; Fig. 7A). We also detected apoptosis induced by VCR and Dex. The data showed that the proportion of apoptotic cells was significantly increased in CA46shB7-H6 cells compared to CA46 cells (19.2 vs. 11.0%, P<0.01 and 26.0 vs. 12.6%, P<0.01; Fig. 7C and D). Our previous studies showed that knockdown of B7-H6 inhibited induced cell apoptosis and influenced expression of apoptosis-associated proteins. To verify whether the sensitization of cells to chemotherapeutic drugs was also associated with these proteins, we analyzed the expressions of representative proteins by western blotting. We observed that the expression of Bcl-2, Bcl-xL, Caspase-3, Survivin, and c-Myc was decreased more in drug-treated CA46shB7-H6 group compared to drug-treated CA46 or CA46shCtrl groups (lane 6 vs. lane 2 and lane 6 vs. lane 4; Fig. 7B). Our findings support the notion that sensitization to chemotherapeutic drugs is mediated by apoptosis-related proteins. These results suggest that knockdown of B7-H6 improves the chemosensitivity of B-cell lymphoma cells.

Knockdown of B7-H6 leads to inactivation of STAT3

STAT3 is often constitutively activated in lymphoma cells (2123), and is involved in oncogenesis. To evaluate whether loss of STAT3 activation was involved in the effects induced by B7-H6 knockdown, we reactivated STAT3 with IL-6, an activator of STAT3 pathway (24), and detected the expression of its target genes. We observed that expression of pSTAT3, pERK1/2, Cyclin D1 and Bcl-xL was decreased in CA46shB7-H6 cells, but increased by IL-6 (P<0.05; Fig. 8), thus indicating that knockdown of B7-H6 leads to inactivation of STAT3.


Immunotherapy has shown some glimmers of hope for the treatment of lymphomas (2). Monoclonal antibodies targeting B7 family checkpoint regulators including PD-L1, B7-H3 and B7-H4 have beneficial effects in reducing tumor burden in melanoma, lung cancer and renal cancer (10,11). B7-H6 is a new member of B7 family and is highly expressed in various tumors (3,5,18) while being absent from normal tissue (3). Such differential expression makes B7-H6 an attractive therapeutic target. B7-H6 expression is negatively associated with overall survival in ovarian cancer (4) and of modest value as a prognostic marker in non-small cell lung cancer and gastric cancer (19,20). Our results also showed that B7-H6 is widely expressed in various hematologic malignancies (data not shown) including B-cell lymphomas, in both primary tumor cells and B-cell lymphoma cell lines. However, it remains to be determined whether B7-H6 expression is associated with outcome in a large cohort of patients with lymphoma.

In this study, we first generated and validated a B-cell lymphoma cell line with B7-H6 knockdown using lentivirus transduction of CA46. B7-H6 expression was significantly decreased at the mRNA and protein level in CA46 cells. The B7-H6 knockdown was specific and efficient, and the B-cell lymphoma cell model was used in the subsequent studies.

Uncontrolled proliferation is one of the important hallmarks of tumor cells (25). Previous studies found that B7-H6 expression is positively correlated with ovarian cancer progression (4), but to date no similar study has been published in B-cell lymphoma. We found that B7-H6 silencing inhibited the proliferation and colony formation of lymphoma cells and the expression of Survivin, PCNA and c-Myc was decreased in CA46shB7-H6 cells. Survivin and PCNA are important molecular markers for proliferation and expressed in G2/M and S phase, respectively (26,27). Translocation involving c-Myc is characteristic of Burkitt lymphomas (28). The inhibition of cell proliferation might be through downregulation of PCNA, Survivin and c-Myc, however, the molecular mechanisms need further investigations.

Resistance to cell death is also a characteristic of tumor cells (25). Previous studies suggested that high soluble B7-H6 was associated with chemoresistance in neuroblastoma (6). To determine whether B7-H6 silencing influences apoptosis in CA46 cells, we measured the apoptotic rates induced by serum starving and chemotherapeutic drugs. We measured an increased rate of apoptosis in the B7-H6 knockdown group. Bcl-2/Bcl-xL and Bax/Bad are important members of Bcl-2 family, which plays a role in cell apoptosis (29,30). The main function of Bcl-2/Bcl-xL is to prevent the release of pro-apoptotic molecules leaking into cytosol to block apoptosis, and the role of Bax/Bad is quite the opposite (30). The induction of apoptosis is influenced by the ratio of pro-apoptotic to anti-apoptotic molecules. Our data showed that the expression of Bcl-2 and Bcl-xL were decreased, and the expression of Bax and Bad was increased in CA46shB7-H6 group. Moreover, the expression of Caspase-8 and -3, which act as initiator and executor of apoptosis, respectively, was decreased after B7-H6 silencing (31). Thus, our study indicates that knockdown of B7-H6 induces apoptosis and chemotherapeutic susceptibility in lymphoma cells through downregulation of anti-apoptotic proteins, upregulation of pro-apoptotic proteins and activation of Caspase-8 and -3.

Disturbance of cell cycle regulation has been shown to be responsible for the initiation and development of solid and hematologic tumors (3234). We assessed cell cycle distribution and found that B7-H6 silencing induced cell cycle arrest in G0/G1 phase. The Cyclin D1-CDK4/6-Rb pathway is a key regulator of the G1/S transition (35,36). Cyclin D1 interacts with CDK4/6 to form a complex, which phosphorylates and inactivates Rb (34). The phosphorylated Rb protein is released from the transcription factor E2F to promote G1/S transition (34). We found that knockdown of B7-H6 led to decreased expressions of Cyclin D1, CDK4, CDK6, pRb proteins and to increased expression of Rb. The p21 protein is a CDK inhibitor that binds to the Cyclin D1-CDK4/6 complex and mediates cell G1 cycle arrest (37). As shown in Fig. 5C, the expression of p21 was reduced after B7-H6 silencing. These data suggest that the cell cycle might be regulated by B7-H6 through the Cyclin D1-CDK4/6-Rb axis and p21.

Invasion and metastasis are important hallmarks of tumors (25). Several studies reported that B7-H6 is associated with metastasis in ovarian cancer (4) and neuroblastoma (6). In our study, we observed that B7-H6 silencing inhibited the migratory and invasive properties of CA46 cells. Since MMP-2 and MMP-9 are correlated with invasion and metastasis in lymphomas and solid tumors (38,39), we measured the expressions of these proteins and found them to be decreased in CA46shB7-H6 cells. This observation indicates that inhibition of cell migration and invasion after B7-H6 silencing might be related to downregulation of MMP-2 and MMP-9.

STAT3 plays a critical role in cancer progression (40) and is a promising target for the treatment of multiple malignancies including lymphoma (22,23,40). Inhibition of STAT3 results in decreased proliferation and increased apoptosis in cancer cells (40). In this study, B7-H6 silencing inhibited the activation of STAT3 and ERK1/2. We reactivated the STAT3 pathway with IL-6 and measured downstream targets of STAT3, including Cyclin D1, Bcl-xL and ERK1/2 (40). The data indicated that knockdown of B7-H6 led to dephosphorylation of STAT3 and downregulation of its target proteins. Thus, our data support a model in which B7-H6 inhibition is responsible for decreased tumor cell oncogenicity and increased apoptosis via abrogation of the STAT3 pathway.

Above all, this study confirmed that B7-H6 was widely expressed in lymphomas. Knockdown of B7-H6 not only suppressed cell proliferation, migration and invasion ability, but also enhanced G0/G1 cycle arrest, apoptosis and chemo-sensitivity in lymphoma cells. This study indicated that B7-H6 inhibition exerts antitumor effects via the inactivation of the STAT3 pathway. These findings suggest that B7-H6 may serve as a therapeutic target in lymphomas.



homologue 6


non-Hodgkin lymphoma


fetal bovine serum






proliferating cell nuclear antigen



Forman D, Bray F and Brewster D: Cancer Incidence in Five Continents Vol X (eletronic version). IARC; Lyon: 2013, Accessed January 2, 2014


Zappasodi R, de Braud F and Di Nicola M: Lymphoma immunotherapy: Current status. Front Immunol. 6:4482015. View Article : Google Scholar : PubMed/NCBI


Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Chabannon C, et al: The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 206:1495–1503. 2009. View Article : Google Scholar : PubMed/NCBI


Zhou Y, Xu Y, Chen L, Xu B, Wu C and Jiang J: B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer. Int J Clin Exp Pathol. 8:9428–9433. 2015.PubMed/NCBI


Wu MR, Zhang T, DeMars LR and Sentman CL: B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity. Gene Ther. 22:675–684. 2015. View Article : Google Scholar : PubMed/NCBI


Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vély F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, et al: Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med. 7:283ra552015. View Article : Google Scholar : PubMed/NCBI


Kellner C, Maurer T, Hallack D, Repp R, van de Winkel JG, Parren PW, Valerius T, Humpe A, Gramatzki M and Peipp M: Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. J Immunol. 189:5037–5046. 2012. View Article : Google Scholar : PubMed/NCBI


Wu MR, Zhang T, Gacerez AT, Coupet TA, DeMars LR and Sentman CL: B7H6-specific bispecific T cell engagers lead to tumor elimination and host antitumor immunity. J Immunol. 194:5305–5311. 2015. View Article : Google Scholar : PubMed/NCBI


Mir MA and Agrewala JN: Signaling through CD80: An approach for treating lymphomas. Expert Opin Ther Targets. 12:969–979. 2008. View Article : Google Scholar : PubMed/NCBI


Philips GK and Atkins M: Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 27:39–46. 2015. View Article : Google Scholar


Leung J and Suh WK: The CD28-B7 family in anti-tumor immunity: Emerging concepts in cancer immunotherapy. Immune Netw. 14:265–276. 2014. View Article : Google Scholar :


Seliger B and Quandt D: The expression, function, and clinical relevance of B7 family members in cancer. Cancer Immunol Immunother. 61:1327–1341. 2012. View Article : Google Scholar : PubMed/NCBI


Zhang W, Wang Y, Wang J, Dong F, Zhu M, Wan W, Li H, Wu F, Yan X and Ke X: B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity. Int J Oncol. 46:2562–2572. 2015.PubMed/NCBI


Li Y, Wang J, Li C and Ke XY: Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy. Leuk Lymphoma. 53:2015–2023. 2012. View Article : Google Scholar : PubMed/NCBI


Kaifu T, Escalière B, Gastinel LN, Vivier E and Baratin M: B7-H6/NKp30 interaction: A mechanism of alerting NK cells against tumors. Cell Mol Life Sci. 68:3531–3539. 2011. View Article : Google Scholar : PubMed/NCBI


Zhang T, Wu MR and Sentman CL: An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo. J Immunol. 189:2290–2299. 2012. View Article : Google Scholar : PubMed/NCBI


Schlecker E, Fiegler N, Arnold A, Altevogt P, Rose-John S, Moldenhauer G, Sucker A, Paschen A, von Strandmann EP, Textor S, et al: Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res. 74:3429–3440. 2014. View Article : Google Scholar : PubMed/NCBI


Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M and Cerwenka A: Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood. 122:684–693. 2013. View Article : Google Scholar : PubMed/NCBI


Chen XJ, Shen J, Zhang GB and Chen WC: B7-H6 protein expression has no prognostic significance in human gastric carcinoma. Pathol Oncol Res. 20:203–207. 2014. View Article : Google Scholar


Zhang X, Zhang G, Qin Y, Bai R and Huang J: B7-H6 expression in non-small cell lung cancers. Int J Clin Exp Pathol. 7:6936–6942. 2014.PubMed/NCBI


Baran-Marszak F, Boukhiar M, Harel S, Laguillier C, Roger C, Gressin R, Martin A, Fagard R, Varin-Blank N, Ajchenbaum-Cymbalista F, et al: Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. Haematologica. 95:1865–1872. 2010. View Article : Google Scholar : PubMed/NCBI


Munoz J, Dhillon N, Janku F, Watowich SS and Hong DS: STAT3 inhibitors: Finding a home in lymphoma and leukemia. Oncologist. 19:536–544. 2014. View Article : Google Scholar : PubMed/NCBI


Soldini D, Montagna C, Schüffler P, Martin V, Georgis A, Thiesler T, Curioni-Fontecedro A, Went P, Bosshard G, Dehler S, et al: A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome. Ann Oncol. 24:193–201. 2013. View Article : Google Scholar


Lu S, Gao Y, Huang X and Wang X: GYY4137, a hydrogen sulfide (H2S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. Int J Oncol. 44:1259–1267. 2014.PubMed/NCBI


Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI


He C, Liu Z, Ji J and Zhu H: Prognostic value of survivin in patients with non-Hodgkin's lymphoma: A meta-analysis. Int J Clin Exp Med. 8:5847–5854. 2015.PubMed/NCBI


Wang SC: PCNA: A silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 35:178–186. 2014. View Article : Google Scholar : PubMed/NCBI


Said J, Lones M and Yea S: Burkitt lymphoma and MYC: What else is new? Adv Anat Pathol. 21:160–165. 2014. View Article : Google Scholar : PubMed/NCBI


Brinkmann K and Kashkar H: Targeting the mitochondrial apoptotic pathway: A preferred approach in hematologic malignancies? Cell Death Dis. 5:e10982014. View Article : Google Scholar : PubMed/NCBI


Hardwick JM and Soane L: Multiple functions of BCL-2 family proteins. Cold Spring Harb Perspect Biol. 5:a87222013. View Article : Google Scholar


Shalini S, Dorstyn L, Dawar S and Kumar S: Old, new and emerging functions of caspases. Cell Death Differ. 22:526–539. 2015. View Article : Google Scholar


Yang WJ, Yu Z and Qiu LG: Research advances of signal pathway in the pathogenesis of mantle cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 34:1073–1075. 2013.(In Chinese). PubMed/NCBI


Bonn BR, Krieger D and Burkhardt B: Cell cycle regulatory molecular profiles of pediatric T-cell lymphoblastic leukemia and lymphoma. Leuk Lymphoma. 53:557–568. 2012. View Article : Google Scholar


Tamura K: Development of cell-cycle checkpoint therapy for solid tumors. Jpn J Clin Oncol. 45:1097–1102. 2015.PubMed/NCBI


Besson A, Dowdy SF and Roberts JM: CDK inhibitors: Cell cycle regulators and beyond. Dev Cell. 14:159–169. 2008. View Article : Google Scholar : PubMed/NCBI


Migliaccio I, Di Leo A and Malorni L: Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol. 26:568–575. 2014. View Article : Google Scholar : PubMed/NCBI


Dutto I, Tillhon M, Cazzalini O, Stivala LA and Prosperi E: Biology of the cell cycle inhibitor p21(CDKN1A): Molecular mechanisms and relevance in chemical toxicology. Arch Toxicol. 89:155–178. 2015. View Article : Google Scholar


Hazar B, Polat G, Seyrek E, Bağdatoğlğlu O, Kanik A and Tiftik N: Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in Hodgkin's and non-Hodgkin's lymphoma. Int J Clin Pract. 58:139–143. 2004. View Article : Google Scholar : PubMed/NCBI


Suminoe A, Matsuzaki A, Hattori H, Koga Y, Ishii E and Hara T: Expression of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) genes in blasts of infant acute lymphoblastic leukemia with organ involvement. Leuk Res. 31:1437–1440. 2007. View Article : Google Scholar : PubMed/NCBI


Xiong A, Yang Z, Shen Y, Zhou J and Shen Q: Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers (Basel). 6:926–957. 2014. View Article : Google Scholar

Related Articles

Journal Cover

Volume 48 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Spandidos Publications style
Wu F, Wang J and Ke X: Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma. Int J Oncol 48: 1561-1570, 2016
Wu, F., Wang, J., & Ke, X. (2016). Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma. International Journal of Oncology, 48, 1561-1570.
Wu, F., Wang, J., Ke, X."Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma". International Journal of Oncology 48.4 (2016): 1561-1570.
Wu, F., Wang, J., Ke, X."Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma". International Journal of Oncology 48, no. 4 (2016): 1561-1570.